Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD

References

• MullerovaHMaselliDJLocantoreNHospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohortChest20151474999100725356881
   PubMed Web of Science ®Google Scholar
• Soler-CatalunaJMartinez-GarciaMRoman SánchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• HartlSLopez-CamposJLPozo-RodriguezFRisk of death and readmission of hospital-admitted COPD exacerbations: European COPD AuditEur Respir J201647111312126493806
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMRabeKFRoflumilast: a review of its use in the treatment of COPDInt J Chron Obstruct Pulmon Dis201611819026792988
   PubMed Web of Science ®Google Scholar
• BatemanEDRabeKFCalverleyPMRoflumilast with long-acting {beta}2 agonists for COPD: influence of exacerbation historyEur Respir J201138355356021737553
   PubMed Web of Science ®Google Scholar
• CalverleyPMRabeKFGoehringUMM2-124 and M2-125 Study GroupsRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
   PubMed Web of Science ®Google Scholar
• MartinezFJCalverleyPMGoehringUMBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet2015385997185786625684586
   PubMed Web of Science ®Google Scholar
• RabeKFCalverleyPMAMartinezFJFabbriLMEffect of roflu-milast in patients with severe COPD and a history of hospitalisationEur Respir J2017501170015828679611
   PubMed Web of Science ®Google Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
   PubMed Web of Science ®Google Scholar
• CalverleyPMMartinezFJFabbriLMGoehringUMRabeKFDoes roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocolInt J Chron Obstruct Pulmon Dis2012737538222791991
   PubMed Web of Science ®Google Scholar
• MartinezFJRabeKFSethiSEffect of roflumilast and inhaled corticosteroid/long-acting beta2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trialAm J Respir Crit Care Med2016194555956727585384
   PubMed Web of Science ®Google Scholar
• Munoz-EsquerreMDiez-FerrerMMontonCRoflumilast added to triple therapy in patients with severe COPD: a real life studyPulm Pharmacol Ther201530162125445930
   PubMed Web of Science ®Google Scholar
• LahuGFaciusAApplication of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerabilityInt J Clin Pharmacol Ther2013511183283624152603
   PubMed Web of Science ®Google Scholar
• RabeKFRoflumilast for the treatment of chronic obstructive pulmonary diseaseExpert Rev Respir Med20104554355520649375
   PubMedGoogle Scholar
• RabeKFUpdate on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseaseBr J Pharmacol20111631536721232047
   PubMed Web of Science ®Google Scholar
• LahuGHunnemeyerADilettiEPopulation pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event modelClin Pharmacokinet201049958960620690782
   PubMed Web of Science ®Google Scholar
• FaciusABagulNGardinerPWatzHPharmacokinetics of a 4-week up-titration regimen of roflumilast in the OPTIMIZE studyAm J Respir Crit Care Med2017195A1337
   Web of Science ®Google Scholar
• ZhangJYuKFWhat’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomesJAMA199828019169016919832001
   PubMed Web of Science ®Google Scholar
• LeungLKPatafioFMRosserWWGastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysisBMC Clin Pharmacol2011111521955317
   PubMedGoogle Scholar
• Drugs.com [webpage on the Internet]Varenicline Tablets (Dosage) – Summary of Product Characteristics (SPC) – (FDA)2016 [updated March 2, 2017] Available from: https://www.drugs.com/dosage/varenicline.htmlAccessed March 29, 2017
   Google Scholar
• Medicines.org.uk [webpage on the Internet]Vargatef 100 mg and 150 mg Soft Capsules – Summary of Product Characteristics (SPC) – (eMC)2016 [updated March 9, 2017] Available from: https://www.medicines.org.uk/emc/medicine/29790Accessed March 29, 2017
   Google Scholar
• Medicines.org.uk [webpage on the Internet]Esbriet 267 mg Hard Capsules – Summary of Product Characteristics (SPC) – (eMC)2015 [updated August 5, 2016] Available from: https://www.medicines.org.uk/emc/medicine/29932Accessed March 29, 2017
   Google Scholar
• SpinaDPDE4 inhibitors: current statusBr J Pharmacol2008155330831518660825
   PubMed Web of Science ®Google Scholar
• AkabasMHCystic fibrosis transmembrane conductance regulator. Structure and function of an epithelial chloride channelJ Biol Chem200027563729373210660517
   PubMed Web of Science ®Google Scholar
• BlanchardEZlockLLaoAAnchored PDE4 regulates chloride conductance in wild-type and DeltaF508-CFTR human airway epitheliaFASEB J201428279180124200884
   PubMed Web of Science ®Google Scholar
• Boswell-SmithVCazzolaMPageCPAre phosphodiesterase 4 inhibitors just more theophylline?J Allergy Clin Immunol200611761237124316750981
   PubMed Web of Science ®Google Scholar
• HatzelmannASchudtCAnti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitroJ Pharmacol Exp Ther2001297126727911259554
   PubMed Web of Science ®Google Scholar
• HaunsBHermannRHunnemeyerAInvestigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjectsJ Clin Pharmacol200646101146115316988203
   PubMed Web of Science ®Google Scholar
• BebiaZBuchSCWilsonJWBioequivalence revisited: influence of age and sex on CYP enzymesClin Pharmacol Ther200476661862715592333
   PubMed Web of Science ®Google Scholar
• MangoniAAJacksonSHAge-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applicationsBr J Clin Pharmacol200457161414678335
   PubMed Web of Science ®Google Scholar
• HwangHShinJYParkKREffect of a dose-escalation regimen for improving adherence to roflumilast in patients with chronic obstructive pulmonary diseaseTuberc Respir Dis (Seoul)201578432132526508918
   PubMedGoogle Scholar